Meanwhile, CB1 antagonists and inverse agonists have been developed for therapeutic applications in obesity-related metabolic disorders, mental illness, liver fibrosis, and nicotine addiction18–20. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.